▶ MAZDUTIDE · SUBTOPIC · MECHANISM
MAZDUTIDE Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Innovent Biologics dual GLP-1 and glucagon receptor agonist (IBI362), derived from oxyntomodulin lineage. Approved in China 2024 for chronic weight management. Phase 3 GLORY program ongoing.
PHARMACOKINETIC HALF-LIFE
Reported half-life for MAZDUTIDE: ~7 days (once-weekly). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Zhao 2024 JAMA Netw Open · placebo-subtracted weight loss ~11.1% at 9 mg/wk over 24 weeks in Chinese adults.
HbA1c reduction in Chinese T2D Phase 2.
48-week Phase 3 obesity met primary endpoint; China NMPA review 2024-2025.
MECHANISM Q+A
▶ How is the GLP-1 / glucagon dual agonist (β) different from the GLP-1 / glucagon dual agonist?
Both are GLP-1/glucagon dual agonists. the GLP-1 / glucagon dual agonist (β) is developed primarily for the Chinese market by Innovent under license from the originator pharma sponsor; the GLP-1 / glucagon dual agonist is the originator pharma sponsor/Zealand's molecule for the global market. Different sequence, similar mechanism.
▶ How does it work?
Dual agonism at the GLP-1 and glucagon receptors. GLP-1 arm drives satiety + glucose-dependent insulin secretion; glucagon arm drives hepatic lipolysis + energy expenditure.
CITED LITERATURE
- Zhao H, et al.. the GLP-1 / glucagon dual agonist (β) IBI362 in obese Chinese adults: dose-finding phase 2. JAMA Netw Open 2024. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19